Last spring, drugmaker Amgen Inc. announced plans to buy Microsoft Corp.’s Copilot AI assistant for 20,000 employees. It was a timely endorsement of the software company’s multibillion-dollar bet on generative artificial intelligence, and Microsoft touted its new Copilot customer in three separate case studies.Thirteen months later, Amgen employees are using a rival product: OpenAI’s ChatGPT....